Day One Biopharmaceuticals (NASDAQ:DAWN) Stock Rating Lowered by JonesTrading

Day One Biopharmaceuticals (NASDAQ:DAWN) was downgraded by analysts at JonesTrading from a “buy” rating to a “hold” rating in a research note issued to investors on Friday, MarketBeat reports. They presently have a $21.50 price target on the stock, up from their prior price target of $20.00. JonesTrading’s target price suggests a potential upside of 1.42% from the company’s previous close.

A number of other research analysts have also issued reports on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Day One Biopharmaceuticals in a report on Monday, December 29th. Oppenheimer reissued a “market perform” rating on shares of Day One Biopharmaceuticals in a report on Friday. JPMorgan Chase & Co. raised their price target on shares of Day One Biopharmaceuticals from $26.00 to $27.00 and gave the company an “overweight” rating in a research note on Friday, November 7th. Wedbush lifted their price target on shares of Day One Biopharmaceuticals from $29.00 to $30.00 and gave the stock an “outperform” rating in a report on Wednesday, February 25th. Finally, HC Wainwright reduced their price objective on shares of Day One Biopharmaceuticals from $25.00 to $22.00 and set a “buy” rating on the stock in a research note on Wednesday, February 25th. Four investment analysts have rated the stock with a Buy rating, six have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, Day One Biopharmaceuticals has a consensus rating of “Hold” and a consensus price target of $25.56.

Day One Biopharmaceuticals Stock Up 65.9%

Shares of DAWN stock opened at $21.20 on Friday. Day One Biopharmaceuticals has a twelve month low of $5.64 and a twelve month high of $21.23. The stock’s fifty day simple moving average is $11.10 and its 200 day simple moving average is $9.06. The firm has a market capitalization of $2.19 billion, a P/E ratio of -20.58 and a beta of -1.25.

Day One Biopharmaceuticals (NASDAQ:DAWN) last posted its earnings results on Tuesday, February 24th. The company reported ($0.21) EPS for the quarter, missing the consensus estimate of ($0.17) by ($0.04). Day One Biopharmaceuticals had a negative net margin of 67.85% and a negative return on equity of 23.43%. The firm had revenue of $53.72 million during the quarter, compared to the consensus estimate of $49.81 million. As a group, equities research analysts expect that Day One Biopharmaceuticals will post -0.72 EPS for the current fiscal year.

Insider Buying and Selling

In related news, insider Adam Dubow sold 6,395 shares of the business’s stock in a transaction on Tuesday, February 17th. The shares were sold at an average price of $11.60, for a total value of $74,182.00. Following the transaction, the insider owned 72,694 shares in the company, valued at $843,250.40. The trade was a 8.09% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO Charles N. York II sold 6,065 shares of the company’s stock in a transaction on Tuesday, February 17th. The shares were sold at an average price of $11.60, for a total transaction of $70,354.00. Following the sale, the chief financial officer directly owned 312,025 shares in the company, valued at $3,619,490. This trade represents a 1.91% decrease in their position. The SEC filing for this sale provides additional information. In the last 90 days, insiders sold 36,461 shares of company stock worth $422,948. Corporate insiders own 6.20% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in DAWN. Federated Hermes Inc. bought a new stake in shares of Day One Biopharmaceuticals during the 3rd quarter valued at about $39,000. Mirae Asset Global Investments Co. Ltd. increased its holdings in Day One Biopharmaceuticals by 26.0% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,989 shares of the company’s stock worth $46,000 after purchasing an additional 1,029 shares in the last quarter. Ameritas Investment Partners Inc. lifted its stake in Day One Biopharmaceuticals by 44.5% in the second quarter. Ameritas Investment Partners Inc. now owns 7,349 shares of the company’s stock valued at $48,000 after buying an additional 2,264 shares during the period. Quarry LP bought a new position in shares of Day One Biopharmaceuticals during the 3rd quarter worth approximately $49,000. Finally, Entropy Technologies LP bought a new position in shares of Day One Biopharmaceuticals during the 2nd quarter worth approximately $67,000. 87.95% of the stock is owned by institutional investors.

Day One Biopharmaceuticals News Roundup

Here are the key news stories impacting Day One Biopharmaceuticals this week:

• Positive Sentiment: Acquisition announced — Servier agreed to buy Day One for $21.50 per share in cash (~$2.5 billion), a deal that crystallizes a takeover premium and explains the sharp rally; the transaction is subject to customary closing conditions and is expected to close in Q2 2026. Article Title
• Positive Sentiment: Analyst target raised — JonesTrading reiterated a “hold” but increased its price target to $21.50 (from $20.00), putting its target in line with the buyout price and reinforcing the deal valuation. Article Title
• Positive Sentiment: Options and volume spike — Unusual call-option activity and extremely high trading volume point to takeover-driven speculative buying and arbitrage interest ahead of the deal close (increased open interest and buy-side activity tend to amplify intraday moves).
• Neutral Sentiment: Trading halt — Shares were temporarily halted earlier for “News pending,” a standard market pause when material corporate announcements are imminent; this is procedural and common around M&A.
• Neutral Sentiment: Ratings reaffirmed — Needham and JonesTrading reaffirmed their “hold” ratings (Needham also maintained its view) even as price targets moved; these keep analyst sentiment mixed despite the takeover. Article Title
• Negative Sentiment: Multiple shareholder investigations and potential litigation — Several law firms (e.g., Brodsky & Smith, Ademi LLP, Halper Sadeh, Monteverde & Associates) announced probes into whether the Board obtained a fair price and followed a proper process; lawsuits or injunctions could delay closing, increase deal costs, or put pressure on the eventual net proceeds to shareholders. Article Title Article Title

Day One Biopharmaceuticals Company Profile

Day One Biopharmaceuticals, Inc (NASDAQ: DAWN) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted therapies for oncology. The company employs a precision medicine approach, leveraging biomarker-driven strategies to identify patient populations most likely to respond to its investigational compounds. By concentrating on well-validated molecular drivers of cancer, Day One seeks to deliver first-in-class or best-in-class therapies with the potential for meaningful clinical benefit.

The company’s pipeline includes several small-molecule candidates in various stages of development.